HS
Therapeutic Areas
CMP Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Norliqva® (Amlodipine Oral Solution) | Hypertension | Approved |
| Tadliq® (Tadalafil Oral Suspension) | Pulmonary Arterial Hypertension | Approved |
| Atorvastatin Oral Liquid Suspension | Hypercholesterolemia | Approved |
| CaroSpir® (Spironolactone Oral Suspension) | Heart Failure, Edema, Hypertension | Approved |
| SPS® Suspension (Sodium Polystyrene Sulfonate) | Hyperkalemia | Approved |
| Isoniazid Oral Solution, USP | Tuberculosis | Approved |
| Oracit® | Metabolic Acidosis | Approved |
| Absorbase® | Contact Dermatitis | Approved |
Leadership Team at CMP Pharma
BB
Brad Barger
Chief Transformation Officer & CFO
AP
Anthony Pipho
Vice President, Operations
JD
Jonathan D. Kuhn
Vice President of Commercial
ML
Melanie Little
Director of Quality Assurance
EG
Emily Gunner
Associate General Counsel and Director of Compliance